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Abstract 
 
A new immunosensor is presented for human chorionic gonadotropin (hCG), made by electro-
depositing Chitosan/gold-nanoparticles over graphene screen-printed electrode (SPE). The antibody 
was covalently bound to CS via its Fc-terminal. The assembly was controlled by electrochemical 
Impedance Spectroscopy (EIS) and followed by Fourier Transformed Infrared (FTIR). The hCG-
immunosensor displayed linear response against the logarithm-hCG concentration for 0.1-25ng/mL 
with limit of detection of 0.016ng/mL. High selectivity was observed in blank urine and successful 
detection of hCG was also achieved in spiked samples of real urine from pregnant woman. The 
immunosensor showed good detection capability, simplicity of fabrication, low-cost, high sensitivity 
and selectivity. 
 
Keywords  
Immunosensor; Screen-printed electrode; Graphene; Antibody; Chitosan; human chorionic 
gonadotropin.
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1. Introduction  
Immunosensors make use of antigen-antibody interactions [1, 2] to detect a wide range of analytes 
which are of great interest in medical diagnostics, environmental analysis, and forensic medicine [3, 
4], including pathogens [5], drugs [6], bacteria [7], toxins [8], and biomarkers [9]. Overall, 
immunosensors employ the same chemical approach of earliest immunoassays, but offer quicker and 
simpler analytical procedures that may be conducted at the point-of-care [10]. Immunosensors use an 
antibody immobilized as a transducer. Antigen-antibody binding event result in electrical or optical 
changes.  
The interaction of the antigen with the immobilized antibody may be monitored using several 
detection methods. In this context, electrochemical immunosensors are increasingly being used for 
biosensing applications [11]. Electrochemical impedance spectroscopy (EIS) is an electrochemical 
technique, facilitating label-free detection [12, 13], thereby yielding significant advantages in terms 
of simplicity and rapidity compared to conventional immunosensing processes.  
The immobilization of an antibody on the transducer element is a crucial step in the preparation of 
immunosensors [14] [15]. Physical adsorption is the simplest immobilization method, but it suffers 
from random antibody orientation and poor reproducibility [16-18]. Approximately 90% of the 
antibodies are in an inactive orientation, due to steric blocking of antigen binding sites on these 
antibodies [12, 19]. More-stable and reproducible antibody binding is achieved by covalent 
attachment, but this attachment must ensure that antigen binding sites are kept free [20]. For this 
purpose, antibody coupling to protein G/A has been used [21].  
An alternative (simple and effective) method for Ab attachment uses chemical activation of the 
carboxylic groups at the Fc terminal of the antibody and subsequent covalent binding to the physical 
support [21, 22]. Although the antibodies may suffer from cross-linking by this process, the 
sensitivity and the reproducibility of such immunosensors are both enhanced when compared to 
random adsorption [21, 22] and the simplicity of the overall process dramatically improves when 
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compared to other oriented-binding approaches. Such Ab modification requires subsequent binding 
to a transducing support carrying an amine layer.  
Chitosan (CS) is a biocompatible natural polymeric material displaying excellent film forming and 
adhesion ability [23], and thereby may act as an excellent amine surface for Ab binding. The 
solubility of CS is limited but it may be achieved by ensuring acidic conditions leading to the 
protonation of the multiple amine groups in the material (pKa of 6.3) [24] [25]. Moreover, the 
deposition of CS films can be performed by using simple electrochemical approach [26, 27] [25]: at 
a constant electrode potential, protons are consumed at the cathode, resulting in a pH gradient being 
established in the vicinity of the cathode surface and yielding a stable and reproducible CS film. The 
limited electrical properties of this film are contoured by including highly conductive and 
biocompatible nanomaterials, such as gold nanoparticles (AuNPs) within the CS film [27].  
The electrical properties of the transducing material to which the CS film is bound are also of major 
relevance in electrical immunosensing. The most widely employed electrode material has been gold, 
but carbon-based nanostructures are now gaining increasing interest. Different carbon 
nanostructures, with different inherent electrical properties have been employed in this context, 
mostly carbon nanotubes (CNTs) [28, 29] and more recently (since 2005) graphene [30]. Graphene 
displays a combination of interesting properties, such large surface area, high electrical conductivity 
and biocompatibility [31-38]. Heterogeneous electron transfer (the transfer of electrons between 
graphene and molecule in solution, necessary for the oxidation/reduction of said molecule) occurs at 
the edges or at defects in the graphene basal plane [39]. Additional defects are introduced by 
functionalizing graphene materials, a necessary procedure for the antibody attachment to graphene, 
also inducing electron transfer. Overall, graphene is a suitable electrical nanomaterial for electrode 
support in immunosensing, but it is mostly employed as a composite material. 
Thus, this paper proposes a new approach for immunosensing using a combination of electro-
deposition of CS and AuNPs on a graphene support and subsequent binding of activated antibodies 
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to this nanocomposite film. This combination was used to follow the human chorionic gonadotropin 
(hCG) in urine, a 37 kDa glycoprotein hormone, secreted by the trophoblastic cells of placenta [40], 
acting as an important diagnostic marker of early pregnancy. In healthy human serum and urine, the 
concentration of hCG is extremely low. The increased level of hCG in serum and urine is associated 
with the trophoblastic cancer and many diseases related to pregnancy [41]. Levels can first be 
detected by a blood test about 11 days after conception and about 12 - 14 days after conception by a 
urine test. In general the hCG levels will double every 72 hours. The level will reach its peak in the 
first 8 – 11 weeks of pregnancy and then will decline and level off for the remainder of the 
pregnancy. There is really no single "normal" hCG level in early pregnancy and there is a very wide 
range of hCG values as pregnancy progresses. hCG is also produced by trophoblast cells in 
hydatidiform moles and choriocarcinoma (trophoblast diseases) in patients with germ cell tumors 
(testicular choriocarcinoma, placental site tumors and germ cell carcinomas of the ovary) and 
sometimes in patients with other malignancies [41].  
Conventional methods for determining hCG are immunoradiometric assays (IRMA) and enzyme-
linked immunosorbent assays (ELISA) [42]. IRMA is extremely sensitive, but involves radiation 
hazards, complicated washing procedures and is expensive, while the ELISA is less sensitive but 
time-consuming. Several immunosensing devices for hCG have been reported in the literature so far 
[43-47] but simple and low cost procedures are still needed for the routine POC determination of this 
biomarker. Considering that an immunosensor is not reusable and that the antibodies are expensive 
and need special storage conditions, it is very important to establish simple, low cost and rapid 
detection procedures, both at the stage of biosensor development and at its subsequent analytical 
application step.  
All chemical modifications made to the graphene electrode in a commercial SPE have been 
optimized and characterized using EIS and FTIR. The analytical features of the final device have 
been evaluated in buffer and urine samples, and its applicability tested in real urine. 
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2. Experimental Section 
 
2.1 Reagents and solutions 
All chemicals used were of analytical grade and water was mostly ultrapure grade. Potassium 
hexacyanoferrate III (K3[Fe(CN)6]), potassium hexacyanoferrate II (K4[Fe(CN)6]) trihydrate and 
magnesium chloride were obtained from Riedel-deHäen; CS, AuNPs <100nm 99.9%, N-(3-
Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDAC) and bovine serum albumin 
(BSA) were obtained from Sigma; acetic acid was obtained from Carlo Erba; N-Hydroxysuccinimide 
(NHS) and creatinine were obtained from Fluka; Phosphate Buffered Saline (PBS) tablets were 
obtained from Amresco; hCG protein was purchased from Abcam (UK); anti-hCG antibody was 
supplied by Ig Innovations; ammonium chloride and calcium chloride were obtained from Merck; 
sodium dihydrogen phosphate was obtained from Scharlau; potassium sulphate and sodium chloride 
were obtained from Panreac; and urea was obtained from Fragon. 
Firstly, a 1% (v/v) acetic acid solution was prepared in deionised water. Chitosan was then added to 
obtain 0.1% (w/w) solution. Finally, AuNPs were also added to obtain a 1% (v/v) solution. PBS 
solution was prepared by dissolution of 1 tablet of PBS in 100mL of deionised water. EDAC, NHS 
and antibody solutions were prepared in this buffer. Synthetic urine was prepared by mixing several 
individual solutions leading to a final composition of 5×10-6M urea, 5.3×10-6M creatinine, 9.8×10-
7M magnesium chloride, 6.8×10-7M calcium chloride, 3.2×10-6M sodium dihydrogen phosphate, 
3.3×10-6M ammonium chloride, 3.9×10-6M potassium sulphate and 6.5×10-6M sodium chloride. A 
redox probe solution was prepared in PBS buffer and had a concentration of 5.0mmol/L of 
[Fe(CN)6]
3- and 5.0mmol/L of [Fe(CN)6]
4-. 
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2.2 Apparatus 
Electrochemical measurements were conducted with a potentiostat/galvanostat, Metrohm Autolab, 
PGSTAT302N, controlled by Nova software and equipped with a Frequency Response Analysis 
module. Graphene-SPEs were purchased from DropSens (DRP-110GPH) and were composed of a 
carbon counter electrode, an Ag pseudo-reference electrode, and a printed graphene working 
electrode (4mm ). Electrical characterization of SPEs was performed by connecting the SPEs to the 
potentiostat/galvanostat via a suitable switch box (DropSens). 
FTIR measurements were performed using an infrared spectrometer from Thermo Scientific, Smart 
iTR, Nicolet iS10, coupled to an Attenuated Total Reflectance (ATR) accessory also from Thermo 
Scientific, equipped with a Germanium sample holder. 
 
2.3 Procedures for immunosensor assembly 
The chitosan (CS) film was obtained by electrodeposition of chitosan on the graphene-SPE surface 
using chrono amperometry (CA). The three-electrodes of the SPE were covered by a solution of 
0.1% of chitosan and 1% of AuNPs. A potential of -2.5V was applied for 120 sec. 
A drop of activated antibody solution was then casted over the CS-AuNPs film on the working 
electrode, and incubated for 2 hours, at room temperature. The activated antibody solution had been 
pre-prepared, by incubating a 200µg/mL antibody solution in 25 mmol/L EDAC and 50 mmol/L of 
NHS, for 2 hours, at room temperature. Following exposure of the working electrode to the activated 
antibody solution the working electrode was then thoroughly rinsed with PBS and incubated in BSA 
solution (0.5mg/mL in PBS buffer) solution, for 30 minutes. The immunosensor was finally washed 
with PBS buffer and kept at 4ºC before use.  
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2.4 Human Chorionic Gonadotropin binding 
hCG binding to the immobilized antibody was achieved by placing a drop of hCG solution on the 
immunosensor working electrode surface. Different concentrations of hCG solutions, ranging from 
0.01 to 100ng/mL, were prepared by dilution of the 250 ng/mL standard hCG solutions in PBS or 
synthetic urine. hCG was also detected in real urine samples from pregnant women. A period of 20 
minutes was allowed for antigen/antibody binding. This was followed by PBS washing prior to redox 
probe EIS measurements. 
 
2.5 Electrochemical assays 
CV and EIS assays were conducted in triplicate. CV measurements were conducted in 5.0mmol/L of 
[Fe(CN)6]
3- and 5.0mmol/L of [Fe(CN)6]
4-, prepared in PBS buffer, pH 7.4, using a potential scan 
from -0.7 to +0.7V, at 50mV/s. EIS assays were made using the same redox couple [Fe(CN)6]3-/4- 
solution, at a standard potential of +0.10 V, using a sinusoidal potential perturbation with amplitude 
of 100mV and a frequency of 50Hz, logarithmically distributed over a frequency range of 100000-
0.1Hz. Impedance data was fitted to a R(RC) circuit, the simplified Randles circuit, using the Nova 
Software. This circuit included solution resistance (RS), double layer capacitor (Cdl), and charge 
transfer resistance (RCT) components, where double-layer capacitance and charge-transfer resistance 
are in parallel [48].  
The immunosensor response to varying hCG concentrations was assessed by EIS measurements. The 
hCG solutions ranged from 0.01 to 100ng/mL, and were prepared either in PBS buffer pH 7 or in 
synthetic urine. The LOD was the hCG concentration at which the calibration curve corresponded to 
a signal of 3, where  is the standard deviation of EIS blank signals (obtained in the absence of the 
hCG). 
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3. Results and discussion 
 
3.1 Immunosensor assembly 
The first surface modification step consisted of electrochemical oxidation of the graphene support. 
This oxidation produce a clean and reproducible surface, containing several hydroxyl groups (Figure 
1A). Hydroxyl groups display a high electrostatic affinity to amine-based materials such as CS, due 
to inherent electrostatic interactions predominantly in hydrogen bonding.  
 Please insert Figure 1 here  
The solution of CS and AuNPs was then electrodeposited over the oxidized graphene (Figure 1B), 
yielding an amine-terminated layer. Deposition of CS, as a method for producing an amine surface 
was tested in several ways, from drop-casting to electrodeposition, with or without AuNPs. Some of 
the conditions tested yielded a degraded graphene surface, with graphene flakes detaching into 
solution and destroying the working area of the SPE. Optimised conditions led to a stable working 
electrode area modified with CS and AuNPs. 
Following deposition of the CS/AuNP layer, the Ab is attached to the CS via its NH2 groups (Figure 
1C). This was achieved by activating the –COOH groups at the Fc terminal of the antibody to 
orientate it on the sensor platform, with the highest probability of having all binding sites accessible 
for antigen binding. This activation was made using conventional EDAC/NHS chemistry: (1) 
reaction of –COOH with EDAC forms a O-acylisourea intermediate that subsequently reacted with 
NHS to produce a more stable active ester; (2) this ester undergoes nucleophilic substitution with any 
amine group on the surface, resulting in the formation of an amide bond and subsequent covalent 
linkage of the antibody to the biosensor [49]. Any unbound protein was removed from the surface by 
thorough washing with PBS buffer. 
The final stage of the sensor assembly was devoted to blocking any free NH2 binding sites on the 
surface that could participate in non-specific binding. This was done by adding BSA (Figure 1D), a 
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common protein in biological fluids. BSA interacts with any available protein binding site, blocking 
these binding sites to side-proteins in real samples. This reaction also contributed to deactivating 
carboxylic positions, thereby eliminating side-responses from the immunosensor. 
The binding event between hCG and the immunosensor antibody is the final stage of the device 
development (Figure 1E). This event is detected electrochemically. A mathematical relation between 
the analyte concentration and the obtained electrical signal was derived. 
 
3.2 Electrochemical follow-up of the immunosensor 
Chemical modifications taking place at the graphene surface were followed by EIS (Figure 2), by 
monitoring the changes in the electron transfer properties of the iron redox probe [50]. EIS data was 
recorded in the form of Nyquist plot, showing the frequency response of the electrode/electrolyte 
system and an area plot of the imaginary component (-Z``) of the impedance against the real 
component (Z`). The RCT at the electrode surface is given by the semicircle diameter of obtained in 
Nyquist plot and was used to define the interface properties of the electrode.  
 Please insert Figure 2 here  
The non-modified graphene-SPEs showed a very small semicircle at the Nyquist plot, indicating the 
presence of a very fast electron-transfer process on the graphene support (Figure 2A). Subsequent 
deposition of a CS/AuNPs film contributed to an increase in the Rct, thus acting as a barrier to the 
electron transfer of the redox probe. This increase is small but consistent with the presence of a 
polymeric material that has a small fraction of protonated amine functions (bearing the opposite 
charge to that of the redox probe) and AuNPs included in its matrix. Subsequent antibody and BSA 
binding, both protein materials, generated an additional increase in the Rct, indicating as an 
additional barrier to electron transfer processes. All CV assays supported the results of EIS studies 
(Figure 2B), with decreased current peaks after protein binding and an increase in the peak-to-peak 
potential separation. 
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3.3 Qualitative analysis of the immunosensor surface  
Figure 3 shows the FTIR spectra of the different stages of assembly of the immunosensor on 
graphene-SPEs. The bare graphene spectra displayed very small intensity and no significant 
band/peak was observed (pink line).  
The presence of CS on graphene after electrodeposition is shown by the adsorption peak centred at 
3362 cm-1 (blue line), corresponding most probably to a combination of both O-H and N-H 
stretching and intermolecular hydrogen bonding within CS moleculesn [51-53]. Although O-H 
stretching is expected to lead to a very intense absorption peak, the amount of CS on the surface is 
probably too small for this observation. The CS film on graphene also shows two small peaks lying 
within 2850-2950 cm-1 that corresponded to C-H stretching. 
The presence of antigen and antibody on graphene/CS contributes to additional light absorption. No 
peak is evidenced on the corresponding spectra (purple), which is probably a consequence of the low 
transmittance observed, being close to saturation (almost no light is transmitted). Overall, this 
spectra confirms the presence of an additional layer over CS. 
 Please insert Figure 3 here  
 
3.5 Analytical performance 
Figure 4A shows the Nyquist plots of the immunosensor as a function of increasing hCG 
concentrations. The concentration range of hCG used for calibration ranged from 0.1 to 25ng/mL, 
with all solutions prepared in PBS. The corresponding calibration curve was plotted as Rct (extracted 
from the Nyquist plots) against the logarithm of the hCG concentration (inset of Figure 4A). Overall, 
the Rct increased logarithmically over the tested concentration range. The average slope of the Rct 
versus log[hCG, ng/mL] was 0.129KΩ/decade hCG with an R2 correlation coefficient of 0.95. LOD 
was 0.016ng/mL.  
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The analytical response of the immunosensor was considered irreversible, probably related to the 
high affinity between hCG and its antibody.  
 Please insert Figure 4 here  
The sensor was always produced in one day, kept at 4ºC and analysed in the following day. It can be 
said that it is stable for 24 hours, but longer periods may be found when stored at 4ºC (as other 
immunosensors). 
 
3.6 Selectivity of the sensor 
Sensor selectivity was assessed by evaluating the sensor response to the combined effect of any 
nonspecific compounds present in the samples analysed. This was done by calibrating the 
immunosensor-SPE in synthetic urine [54] and assessing any changes within the analytical 
performance of the device. Figure 4B shows the Nyquist plots obtained in this context. 
Unexpectedly, the performance of the device improved, showing a wider log[hCG] response range 
and increased sensitivity. The linear response ranged from 0.1 to 5ng/mL and the average slope was 
of 0.353KΩ/decade.  
Overall, the analytical performance of the immunosensor was unexpectedly enhanced, indicating that 
no interference in the electrical response of the immunosensor was observed and suggesting the 
successful application of the device in real urine samples. 
 
3.7 Application to urine samples 
The values of hCG in real urine samples were determined by EIS measurements after previous 
calibration of the device in real urine of non-pregnant women. The typical Nyquist plots obtained are 
shown in Figure 5, along with the corresponding calibration curve.  
The device exhibited a linear logarithmic behaviour from 0.01 to 1ng/mL, a narrower concentration 
range of linear logarithmic response than that observed with synthetic urine. The biggest difference 
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in terms of analytical performance was reflected in the signal saturation at lower hCG 
concentrations. Ever so, the format of the Rct curve was similar to that of the calibration standards 
(Figure 5), suggesting that the system was operating well when using real urine samples. 
A pristine but unused immunosensor was then used to analyse the urine of a pregnant woman, with a 
pregnancy of 3 to 5 weeks. The concentration of hCG obtained was 3.5ng/mL (17.4mIU/mL), which 
was in agreement with the pregnancy status.  
 Please insert Figure 5 here  
 
4. Conclusions 
In summary, a new impedimetric biosensor for hCG determination in urine has been developed. A 
simple approach for generating a graphene-amined surface to which an antibody binding with a 
suitable orientation for antigen binding is presented. The observed resistance to electron transfer 
increased linearly with increasing of log(hCG) concentration. The sensor response was not affected 
by chemical components present in synthetic urine indicating non-specific binding. 
The sensor has been applied successfully to quantitatively detect hCG in the urine of pregnant 
women, suggesting a successful application in point-of-care diagnostics in the near future. 
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Captions for figures 
 
Figure 1. Schematic illustration of the immunosensor assembly. 
 
Figure 2. - EIS spectra of each stage of the assembly of the immunosensor (A) and CV data taken at each stage (B). (A) Nyquist plots of 
BSA/anti-hCG/CS/Graphene-SPE sensor, obtained in 5.0 mM [Fe(CN)6]3-/4- PBS buffer pH 7.4; (B) CV record after modification of 
Chitosan/AuNPs/Graphene-SPE with antibody and BSA. 
 
Figure 3. FTIR spectra of the graphene-SPEs and graphene modified with CS and Antibody/antigen (spectra on the right correspond to a smaller 
range of wavenumber, focusing the transmittance range of interest). 
 
Figure 4. Calibration curve of the immunosensor. (A): Nyquist plots of BSA/anti hCG/Chitosan/Graphene-SPE sensor, in 5.0 mM [Fe(CN)6]3-/4- 
PBS buffer pH 7.4, previously incubated in increasing concentrations of hCG. (B): Nyquist plots of BSA/anti-hCG/Chitosan/Graphene-SPE 
sensor, in 5.0 mM [Fe(CN)6]3-/4- synthetic urine pH 6.5, previously incubated in increasing concentrations of hCG. 
18 
 
Figure 5. Nyquist plots corresponding to the calibration of the immunosensor in real urine samples with hCG standards in ng/L. Inset: 
corresponding calibration curve, ploting log(hCG) against Rct. 
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Figure 3 
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Relative values 
Figure 4  
0
200
400
600
800
1000
200 700 1200 1700
Z
``
 (
Ω
)
Z` (Ω)
0.1 0.5
1 2.5
5
(B)
0
100
200
300
400
500
600
700
800
900
180 680 1180 1680
Z
``
 (
Ω
)
Z` (Ω)
0.01 0.1 0.5 0.75
1 7.5 25
(A)
y = 0.57 ( 0.06) x+0.82 ( 0.03)
R² = 0.9713
0
0.5
1
1.5
-1 0 1
R
el
a
ti
v
e
 R
log (hCG, ng/mL)
y = 1.17 ( 0.05) x + 4.54 ( 0.05)
R² = 0.9924
0.0
2.0
4.0
6.0
8.0
-2 -1 0 1
R
el
a
ti
v
e 
R
log (hCG, ng/mL)
25 
 
Relative values 
 
Real values 
Figure 5 
0
100
200
300
400
500
600
180 580 980 1380
Z
``
 (
Ω
)
Z` (Ω)
0.01 0.05
0.1 1
y = 0.22 ( 0.067) x+0.69 
( 0.0.087)
R² = 0.8411
0.1
0.3
0.5
0.7
-2 -1 0
R
el
a
ti
v
e 
R
log (hCG, ng/mL)
0
100
200
300
400
500
600
180 580 980 1380
Z
``
 (
Ω
)
Z` (Ω)
0.01 0.05
0.1 1
y = 132.6 ( 40.7) x+1019.6 
( 52.7)
R² = 0.8411
600
800
1000
-2 -1 0
R
ct
 (
Ω
)
log (hCG, ng/mL)
